Sarsasapogenin

Sarsasapogenin at a Glance

Sarsasapogenin is a steroidal sapogenin — the sugar-free steroid core, or aglycone, of a large family of plant saponins. Chemically it is (25S)-5β-spirostan-3β-ol (C₂₇H₄₄O₃, 416.6 Da): a four-ring steroid nucleus with a spiroketal E/F ring system fused on at C-16/C-22, a cis A/B ring junction (the 5β configuration), and the 25S methyl orientation that distinguishes it from its epimer smilagenin ^{1Reference 1Mustafa NH et al. · 2022Chemistry, biosynthesis and pharmacology of sarsasapogenin: a potential natural steroid molecule for new drug design, development and therapyView study →}.

Plants almost never store it free. It circulates in the plant as glycosides: sarsasaponin (parillin) in sarsaparilla (Smilax), the shatavarins in shatavari, and the timosaponins in Anemarrhena asphodeloides (zhi mu). Sarsasapogenin is what is left after those sugars are stripped off — in the laboratory by acid hydrolysis, and in the body by gut bacteria ^{7,9,24Reference 7Lim SM et al. · 2015AnimalTimosaponin AIII and its metabolite sarsasapogenin ameliorate colitis in mice by inhibiting NF-κB and MAPK activation and restoring Th17/Treg cell balanceView study →Reference 9Sun Y et al. · 2015In vitroMetabolites characterization of timosaponin AIII in vivo and in vitro by using liquid chromatography-mass spectrometryView study →Reference 24Love J · 2020Acid hydrolysis of saponins extracted in tinctureView study →}.

Two things about this molecule need stating up front, because both are routinely got wrong.

It is not a hormone precursor. A steroid skeleton is not a hormone, and there is no human enzymatic route from sarsasapogenin to progesterone, DHEA or testosterone. The “plant steroid” framing that sold sarsaparilla as a natural anabolic — and that sells wild yam as natural progesterone — is a misreading of an industrial process (see below) ^{3,28Reference 3MARKER RE · 1947Steroidal sapogeninsView study →Reference 28Komesaroff PA et al. · 2001Effects of wild yam extract on menopausal symptoms, lipids and sex hormones in healthy menopausal womenView study →}.

Its real pharmacology is neurological and anti-inflammatory, and it is overwhelmingly Anemarrhena research, not shatavari or sarsaparilla research. The most interesting finding in the literature — that it raises brain M1 muscarinic receptor density without being a cholinesterase inhibitor or a receptor ligand — comes from the Chinese zhi mu tradition ^{4,5Reference 4Hu Y et al. · 2005AnimalA new approach to the pharmacological regulation of memory: sarsasapogenin improves memory by elevating the low muscarinic acetylcholine receptor density in brains of memory-deficit rat modelsView study →Reference 5Hu Y et al. · 2010AnimalRegulation of M1-receptor mRNA stability by smilagenin and its significance in improving memory of aged ratsView study →}. Almost none of the strong work used the plants this molecule is named after or most often attributed to.

The Steroid-Skeleton Myth — What Sarsasapogenin Does Not Do

Sarsasapogenin sits at the centre of the single most persistent myth in the herbal supplement world, and it deserves a direct answer.

The factual core. In the 1930s and 1940s, Russell Marker’s group showed that the spiroketal side chain of a steroidal sapogenin could be chemically degraded — in a flask, with acetic anhydride, chromium trioxide and heat — to give pregnenolone and from there progesterone and cortisone ^{3Reference 3MARKER RE · 1947Steroidal sapogeninsView study →}. Sarsasapogenin was one of the sapogenins on which that chemistry was worked out; the eventual industrial feedstock was diosgenin from Mexican yam, because its Δ⁵ double bond gave the useful unsaturated pregnane directly. This chemistry is real, it is historically enormous, and it is entirely a factory process.

The human body cannot do it. There is no mammalian enzyme that opens the spiroketal F ring and cleaves the C-20/C-22 bond of a spirostanol. Nothing in human metabolism converts sarsasapogenin, diosgenin or smilagenin into a steroid hormone. The gut-and-liver metabolism that has been mapped for these sapogenins does something entirely different: oxidation and re-reduction at C-3 to give the 3α “epi” isomers, then glucuronidation and biliary excretion ^{25,26Reference 25Flåøyen A · 1997Metabolism of saponins from Narthecium ossifragum — a plant implicated in the aetiology of alveld, a hepatogenous photosensitization of sheepView study →Reference 26Flåøyen A et al. · 2002Ruminal metabolism in sheep of saponins from Yucca schidigeraView study →}. That is a disposal pathway, not a steroidogenic one.

The clinical test was run, on the sister molecule, and it was negative. A double-blind placebo-controlled crossover trial of topical wild yam (diosgenin-bearing) cream in 23 symptomatic menopausal women found no change in serum or salivary progesterone, no change in oestradiol, FSH, lipids or weight, and no separation from placebo on symptoms ^{28Reference 28Komesaroff PA et al. · 2001Effects of wild yam extract on menopausal symptoms, lipids and sex hormones in healthy menopausal womenView study →}. Topical “natural progesterone” creams that do work do so because progesterone was added to them.

And sarsaparilla’s “natural steroid” reputation has no support at all. A PubMed search for sarsasapogenin AND (androgen OR testosterone OR 5-alpha-reductase OR prostate) returns two records, neither of which reports any androgenic effect — one is a fungal biotransformation study, the other a Tribulus-focused review of testosterone phytotherapy that does not test sarsasapogenin at all. There is no evidence that sarsasapogenin raises testosterone in any species.

What it does do to the endocrine system is the opposite direction, and it is worth knowing. In a danazol-induced precocious-puberty model in female rats, sarsasapogenin delayed vaginal opening, reduced uterine and ovarian coefficients, lowered serum LH, FSH and oestradiol, and downregulated hypothalamic GnRH, GnRH-R and Kiss-1 ^{12Reference 12Hu K et al. · 2020Study on the mechanism of sarsasapogenin in treating precocious puberty by regulating the HPG axisView study →}. That is genuine hormone-axis pharmacology — but it is suppression of the reproductive axis, not oestrogenic stimulation. Any page that files sarsasapogenin as a “phytoestrogen” is describing a molecule that, where it has actually been measured on the HPG axis, did the reverse.

Is there any direct receptor evidence? The oestrogen-receptor claim rests on molecular docking, not binding assays: an in-silico screen of 34 uterine-active herbs found sarsasapogenin bound well in the computer to the oestrogen receptor (1X7R), the progesterone receptor and CYP17A1 ^{29Reference 29Narayanan PL · 2025Screening of optimal phytoconstituents through in silico docking, toxicity, pharmacokinetic, and molecular dynamics approach for fighting against polycystic ovarian syndromeView study →}. Docking scores are hypotheses, not affinities. Meanwhile, the one study that pinned down a direct molecular target by physical methods — cellular thermal shift assay plus surface plasmon resonance — found sarsasapogenin binds glutathione peroxidase 4 (GPX4), a ferroptosis-controlling enzyme, with a K_D of 44.6 µM; and in an ovariectomised (oestrogen-deficient) osteoporosis model its benefit was abolished in GPX4-knockout mice ^{11Reference 11Wang F et al. · 2025Sarsasapogenin stimulates angiogenesis and osteogenesis coupling to treat estrogen deficiency-induced osteoporosis by activating the GPX4/SLIT3/ROBO1 axisView study →}. In other words: the best-characterised protein target of this molecule is a peroxidase, not a nuclear hormone receptor, and its effect in an oestrogen-deficiency model runs through that peroxidase.

Aglycone, Not Saponin — Where It Sits On The Chain

Steroidal saponins are large, sugar-heavy glycosides that absorb poorly. The species that reaches tissue is usually the deglycosylated sapogenin liberated by gut bacteria — and sarsasapogenin is that end product for three separate plant lineages:

Glycoside (as eaten)	Source plant	Liberated aglycone
Sarsasaponin / parillin	Sarsaparilla (Smilax)	Sarsasapogenin (+ smilagenin)
Shatavarins I–X	Shatavari (Asparagus racemosus)	Sarsasapogenin 21Reference 21Banerjee P et al. · 2025An updated insight on the chemistry, ethnobotany, and health benefits of Asparagus racemosus (shatavari): with a special emphasis on shatavarin IVView study →
Timosaponin A-III, B-II, B-III	Anemarrhena asphodeloides	Sarsasapogenin 7,9Reference 7Lim SM et al. · 2015AnimalTimosaponin AIII and its metabolite sarsasapogenin ameliorate colitis in mice by inhibiting NF-κB and MAPK activation and restoring Th17/Treg cell balanceView study →Reference 9Sun Y et al. · 2015In vitroMetabolites characterization of timosaponin AIII in vivo and in vitro by using liquid chromatography-mass spectrometryView study →

The shatavari chain is worth spelling out, because it is a three-step ladder and this molecule is the bottom rung. Shatavarin I is a bidesmosidic furostanol saponin (C₅₁H₈₆O₂₃, 1067 Da) — sugars on two separate positions, with the F ring held open by a glucose at C-26. Remove that C-26 glucose and the F ring snaps shut: the result is shatavarin IV, the monodesmosidic spirostanol marker used to standardise the root. Remove the remaining C-3 sugar chain and you have sarsasapogenin. This is the same furostanol→spirostanol→aglycone relationship as protodioscin→dioscin→diosgenin, and it is the reason drying and processing shift a shatavari root’s saponin profile before anyone eats it. The furostanol and spirostanol forms are not interchangeable — but both end at the same aglycone.

This is not a footnote — it is the exposure mechanism, and it has been demonstrated rather than assumed. Timosaponin A-III incubated anaerobically with human intestinal microflora yields sarsasapogenin as the main metabolite ^{8Reference 8Lee B et al. · 2010Inhibitory effects of steroidal timosaponins isolated from the rhizomes of Anemarrhena asphodeloides against passive cutaneous anaphylaxis reaction and pruritusView study →}, and sarsasapogenin was physically isolated from the urine of rats dosed with timosaponin A-III ^{9Reference 9Sun Y et al. · 2015In vitroMetabolites characterization of timosaponin AIII in vivo and in vitro by using liquid chromatography-mass spectrometryView study →}. In every head-to-head, the aglycone was the more potent species: sarsasapogenin beat timosaponin A-III both in vitro and in vivo on colitis endpoints ^{7Reference 7Lim SM et al. · 2015AnimalTimosaponin AIII and its metabolite sarsasapogenin ameliorate colitis in mice by inhibiting NF-κB and MAPK activation and restoring Th17/Treg cell balanceView study →}, and beat it on mast-cell degranulation and passive cutaneous anaphylaxis ^{8Reference 8Lee B et al. · 2010Inhibitory effects of steroidal timosaponins isolated from the rhizomes of Anemarrhena asphodeloides against passive cutaneous anaphylaxis reaction and pruritusView study →}. Timosaponin A-III given by mouth worked; given intraperitoneally — bypassing the gut flora — it barely worked at all ^{8Reference 8Lee B et al. · 2010Inhibitory effects of steroidal timosaponins isolated from the rhizomes of Anemarrhena asphodeloides against passive cutaneous anaphylaxis reaction and pruritusView study →}. That is about as clean a demonstration as this field offers that the glycoside is a prodrug.

One consequence that matters for reading the cytotoxicity literature. Saponins are surfactants: they are membrane-permeabilising and haemolytic in vitro, which is why so many “kills cancer cells at X µM” results in this class are detergent artefacts. Sarsasapogenin is the aglycone — it has no sugar chain and is not a surfactant, so it does not carry the saponin haemolysis problem in the same way. That is a genuine point in its favour. It does not, however, rescue the cancer data: the headline cytotoxicity result (HepG2 hepatoma, IC₅₀ 42.4 µg/mL ≈ 100 µM over 48 h) was reported without a normal-cell comparator and without a selectivity index ^{19Reference 19Bao W et al. · 2007The apoptotic effect of sarsasapogenin from Anemarrhena asphodeloides on HepG2 human hepatoma cellsView study →}, and later medicinal-chemistry work found the parent sapogenins so weakly cytotoxic that derivatives had to be built to get useful potency — one lipophilic cationic derivative was 34-fold more active than diosgenin ^{37Reference 37An RF et al. · 2025Design, synthesis and cytotoxic activity of novel lipophilic cationic derivatives of diosgenin and sarsasapogeninView study →}. A molecule that needs a 34-fold boost to become interesting was not interesting to begin with.

Where a selectivity index was measured on this chemotype, the margin was thin. Four purified A. racemosus saponin glycosides killed hepato- and prostate-carcinoma lines at IC₅₀ 14–37 µM while primary human fibroblasts came in at 22–66 µM ^{41Reference 41Onlom C et al. · 2017Preparative and rapid purification of saponins from Asparagus racemosus root by high performance centrifugal partition chromatographyView study →} — a selectivity ratio of roughly 1.5–2×. The authors reported this as selectivity, and technically it is; but a two-fold window against normal primary cells is exactly the signature of a large non-specific membrane component rather than a targeted mechanism. That is the glycosides, not the aglycone — no equivalent comparator has ever been run for sarsasapogenin itself.

What It's Used For

The research base is real, coherent and almost entirely rodent-stage. It splits into a cholinergic/neurological thread that is the most distinctive thing about this molecule, a broad NF-κB-centred anti-inflammatory thread, and a cluster of diabetic-complication models that are really the anti-inflammatory thread applied to specific tissues.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Every row here is preclinical; no application has human data, so the scale is compressed toward the low end by design.

01Memory, cognition & Alzheimer-like pathologyShaky34%Multiple independent rodent models; a mechanism (M1 density / m1 mRNA) no drug class shares ^{4,5,6,13,15Reference 4Hu Y et al. · 2005AnimalA new approach to the pharmacological regulation of memory: sarsasapogenin improves memory by elevating the low muscarinic acetylcholine receptor density in brains of memory-deficit rat modelsView study →Reference 5Hu Y et al. · 2010AnimalRegulation of M1-receptor mRNA stability by smilagenin and its significance in improving memory of aged ratsView study →Reference 6Kashyap P et al. · 2020Sarsasapogenin: a steroidal saponin from Asparagus racemosus as multi target directed ligand in Alzheimer’s diseaseView study →Reference 13Zhang YM et al. · 2021Sarsasapogenin attenuates Alzheimer-like encephalopathy in diabetesView study →Reference 15Huang C et al. · 2017Sarsasapogenin-AA13 ameliorates Aβ-induced cognitive deficits via improving neuroglial capacity on Aβ clearance and antiinflammationView study →}

02Anti-inflammatory (TLR4 / NF-κB)Shaky31%Macrophage mechanism + colitis, asthma and dermatitis models; aglycone beats the glycoside ^{7,8,33Reference 7Lim SM et al. · 2015AnimalTimosaponin AIII and its metabolite sarsasapogenin ameliorate colitis in mice by inhibiting NF-κB and MAPK activation and restoring Th17/Treg cell balanceView study →Reference 8Lee B et al. · 2010Inhibitory effects of steroidal timosaponins isolated from the rhizomes of Anemarrhena asphodeloides against passive cutaneous anaphylaxis reaction and pruritusView study →Reference 33Mandlik DS et al. · 2021AnimalProtective effect of sarsasapogenin in TNBS induced ulcerative colitis in rats associated with downregulation of pro-inflammatory mediators and oxidative stressView study →}

03Diabetic complicationsShaky27%Streptozotocin rats + high-glucose cells: nephropathy, retinopathy, encephalopathy ^{13,14,31Reference 13Zhang YM et al. · 2021Sarsasapogenin attenuates Alzheimer-like encephalopathy in diabetesView study →Reference 14Kong L et al. · 2021Sarsasapogenin ameliorates diabetes-associated memory impairment and neuroinflammation through down-regulation of PAR-1 receptorView study →Reference 31Choi YH · 2023Reduction of high glucose-induced oxidative injury in human retinal pigment epithelial cells by sarsasapogenin through inhibition of ROS generation and inactivation of NF-κB/NLRP3 inflammasome pathwayView study →}

04Bone loss & osteoporosisShaky23%RANKL/NFATc1 osteoclastogenesis + OVX mice with a physically confirmed target (GPX4) ^{11,18Reference 11Wang F et al. · 2025Sarsasapogenin stimulates angiogenesis and osteogenesis coupling to treat estrogen deficiency-induced osteoporosis by activating the GPX4/SLIT3/ROBO1 axisView study →Reference 18Peng J et al. · 2020In vitroSarsasapogenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents lipopolysaccharide-induced bone loss in vivoView study →}

05Antidepressant & anxiolyticShaky17%One olfactory-bulbectomy model for the parent; the rapid-onset work is a derivative, not the molecule ^{16,17Reference 16Guo F et al. · 2016The rapid antidepressant and anxiolytic-like effects of YY-21 involve enhancement of excitatory synaptic transmission via activation of mTOR signaling in the mPFCView study →Reference 17Feng B et al. · 2017Sarsasapogenin reverses depressive-like behaviors and nicotinic acetylcholine receptors induced by olfactory bulbectomyView study →}

06AnticancerShaky11%Single-line in-vitro apoptosis with no selectivity index; derivatives outperform the parent ^{19,37Reference 19Bao W et al. · 2007The apoptotic effect of sarsasapogenin from Anemarrhena asphodeloides on HepG2 human hepatoma cellsView study →Reference 37An RF et al. · 2025Design, synthesis and cytotoxic activity of novel lipophilic cationic derivatives of diosgenin and sarsasapogeninView study →}

07Hormonal / “phytoestrogen”Shaky6%Molecular docking only; the one measured HPG-axis study shows suppression, not oestrogenicity ^{12,29Reference 12Hu K et al. · 2020Study on the mechanism of sarsasapogenin in treating precocious puberty by regulating the HPG axisView study →Reference 29Narayanan PL · 2025Screening of optimal phytoconstituents through in silico docking, toxicity, pharmacokinetic, and molecular dynamics approach for fighting against polycystic ovarian syndromeView study →}

Mechanisms

The load-bearing contrast: the two mechanisms confirmed by physical binding methods are a muscarinic-receptor-density effect and a peroxidase (GPX4) — neither is a hormone receptor. The steroid skeleton is a structural coincidence, not a functional one.

Pharmacokinetics

Sarsasapogenin is lipophilic and very poorly water-soluble, which dominates its behaviour. A validated LC-MS/MS method in rats gives a half-life of 15.1–16.1 h across 25, 50 and 100 mg/kg intragastric doses, with AUC₀₋₇₂ and C_max both linear with dose across that range ^{10Reference 10Yang B et al. · 2016AnimalQuantitative determination of sarsasapogenin in rat plasma using liquid chromatography-tandem mass spectrometryView study →}; a companion analysis puts t½ at ~17.7 h after 100 mg/kg ^{1Reference 1Mustafa NH et al. · 2022Chemistry, biosynthesis and pharmacology of sarsasapogenin: a potential natural steroid molecule for new drug design, development and therapyView study →}. T_max is markedly later than for the intact timosaponins of A. asphodeloides — the sapogenin appears in blood slowly, consistent with absorption limited by dissolution rather than by permeability ^{1Reference 1Mustafa NH et al. · 2022Chemistry, biosynthesis and pharmacology of sarsasapogenin: a potential natural steroid molecule for new drug design, development and therapyView study →}.

The route of exposure from a herbal preparation is indirect. What is swallowed is a saponin; gut microbiota hydrolyse it to the aglycone, which is then absorbed. Anaerobic incubation of timosaponin A-III with human intestinal microflora yields sarsasapogenin as the main metabolite ^{8Reference 8Lee B et al. · 2010Inhibitory effects of steroidal timosaponins isolated from the rhizomes of Anemarrhena asphodeloides against passive cutaneous anaphylaxis reaction and pruritusView study →}, and sarsasapogenin was isolated from rat urine after oral timosaponin A-III ^{9Reference 9Sun Y et al. · 2015In vitroMetabolites characterization of timosaponin AIII in vivo and in vitro by using liquid chromatography-mass spectrometryView study →}. The ruminant work maps the full disposition with unusual clarity: saponins hydrolyse in the rumen, sapogenins are epimerised at C-3 to the 3α “epi” forms, absorbed in the jejunum, carried to the liver where episarsasapogenin and epismilagenin (but not the 3β parents) are conjugated and excreted into bile, then deconjugated again in the caecum and colon ^{25,26Reference 25Flåøyen A · 1997Metabolism of saponins from Narthecium ossifragum — a plant implicated in the aetiology of alveld, a hepatogenous photosensitization of sheepView study →Reference 26Flåøyen A et al. · 2002Ruminal metabolism in sheep of saponins from Yucca schidigeraView study →}.

Two practical consequences. First, the effective dose from a herb is unknowable — it depends on the saponin content of that batch and on an individual’s gut flora. Second, the long half-life means repeated dosing accumulates; the pharmacology literature’s 20–60 mg/kg rodent regimens are far above anything a botanical delivers.

Clinical Trials

There are none. No clinical trial of isolated sarsasapogenin has been conducted in any indication, and the compound has no regulatory status anywhere. The nearest human data belong to whole plants, and belong to them entirely: a 6-week randomised double-blind trial of shatavari (1000 mg/day) in 20 postmenopausal women improved handgrip strength and raised vastus lateralis myosin regulatory light chain phosphorylation and Akt^ser473 phosphorylation, but found no change in bone-turnover markers — and measured no sapogenin, tested no receptor, and cannot attribute its result to any molecule ^{27Reference 27O’Leary MF et al. · 2021Shatavari supplementation in postmenopausal women improves handgrip strength and increases vastus lateralis myosin regulatory light chain phosphorylation but does not alter markers of bone turnoverView study →}.

Last checked: August 2026.

Sarsasapogenin vs. Smilagenin vs. Diosgenin

Three sapogenins, endlessly confused, differing only in stereochemistry and one double bond — and the differences matter.

	Sarsasapogenin	Smilagenin	Diosgenin
Systematic name	(25S)-5β-spirostan-3β-ol	(25R)-5β-spirostan-3β-ol	(25R)-spirost-5-en-3β-ol
A/B ring fusion	5β (cis)	5β (cis)	Δ⁵ unsaturated
C-25 configuration	S	R	R
Chief sources	Smilax, Anemarrhena, Asparagus	Smilax, Smilax glabra, Asparagus cochinchinensis	Dioscorea, fenugreek, Tribulus
Signature pharmacology	M1 receptor density ↑; TLR4/NF-κB ↓ 4,7Reference 4Hu Y et al. · 2005AnimalA new approach to the pharmacological regulation of memory: sarsasapogenin improves memory by elevating the low muscarinic acetylcholine receptor density in brains of memory-deficit rat modelsView study →Reference 7Lim SM et al. · 2015AnimalTimosaponin AIII and its metabolite sarsasapogenin ameliorate colitis in mice by inhibiting NF-κB and MAPK activation and restoring Th17/Treg cell balanceView study →	M1 mRNA stabilisation; BDNF/P300 histone acetylation 5,35Reference 5Hu Y et al. · 2010AnimalRegulation of M1-receptor mRNA stability by smilagenin and its significance in improving memory of aged ratsView study →Reference 35Yang S et al. · 2023Smilagenin induces expression and epigenetic remodeling of BDNF in Alzheimer’s diseaseView study →	Anti-inflammatory, lipid-lowering, industrial steroid feedstock
Industrial role	the sapogenin the degradation chemistry was worked out on 3Reference 3MARKER RE · 1947Steroidal sapogeninsView study →	—	the commercial feedstock (Δ⁵ gives the useful pregnane)
Converts to hormones in the body	No	No	No

Sarsasapogenin and smilagenin are C-25 epimers and interconvert readily — acid hydrolysis of sarsaparilla tincture yields both, the smilagenin arising by epimerisation of the sarsasapogenin released ^{24Reference 24Love J · 2020Acid hydrolysis of saponins extracted in tinctureView study →}. They are also produced together by ruminant metabolism, and any quantitative claim about one that does not report the other should be treated cautiously ^{25,26Reference 25Flåøyen A · 1997Metabolism of saponins from Narthecium ossifragum — a plant implicated in the aetiology of alveld, a hepatogenous photosensitization of sheepView study →Reference 26Flåøyen A et al. · 2002Ruminal metabolism in sheep of saponins from Yucca schidigeraView study →}. Their pharmacology tracks in parallel: where sarsasapogenin raises M1 receptor density, smilagenin was shown to do so by stabilising m1 mRNA ^{5Reference 5Hu Y et al. · 2010AnimalRegulation of M1-receptor mRNA stability by smilagenin and its significance in improving memory of aged ratsView study →}, and smilagenin from Asparagus cochinchinensis improves cognition in APP/PS1 mice by raising P300 and histone acetylation at the BDNF promoter ^{35Reference 35Yang S et al. · 2023Smilagenin induces expression and epigenetic remodeling of BDNF in Alzheimer’s diseaseView study →}. Diosgenin sits apart — the Δ⁵ double bond makes it the useful factory feedstock, which is precisely why the hormone myth attached itself to wild yam rather than to sarsaparilla.

The Shatavari Attribution Problem

This molecule is most often introduced to English-language readers as “the aglycone of the shatavarins,” and that framing is doing more work than the evidence supports.

The count. A PubMed search for sarsasapogenin AND "Asparagus racemosus" returns seven records. Of those: one is a LactMed lactation monograph on the herb that merely lists the compound among shatavari’s constituents; one is a review ^{21Reference 21Banerjee P et al. · 2025An updated insight on the chemistry, ethnobotany, and health benefits of Asparagus racemosus (shatavari): with a special emphasis on shatavarin IVView study →}; three are in-silico docking or network-pharmacology papers — a PCOS docking screen ^{29Reference 29Narayanan PL · 2025Screening of optimal phytoconstituents through in silico docking, toxicity, pharmacokinetic, and molecular dynamics approach for fighting against polycystic ovarian syndromeView study →}, an epilepsy/dementia network-pharmacology study ^{38Reference 38Kaur B et al. · 2023A network pharmacology approach to explore pharmacological mechanisms of Asparagus racemosus for ameliorative effect in epilepsy and comorbid progressive memory dysfunctionView study →} and an antitubercular docking screen; one is a genuine isolation — a novel sarsasapogenin glycoside (“immunoside”) from A. racemosus that acted as a hepatitis-B vaccine adjuvant in mice ^{22Reference 22Sidiq T et al. · 2011A novel sarsasapogenin glycoside from Asparagus racemosus elicits protective immune responses against HBsAgView study →}; and one is a real in-vitro pharmacology paper on the molecule itself ^{6Reference 6Kashyap P et al. · 2020Sarsasapogenin: a steroidal saponin from Asparagus racemosus as multi target directed ligand in Alzheimer’s diseaseView study →}. That is the entire shatavari-specific literature for this compound.

By contrast, sarsasapogenin AND Anemarrhena returns 43 records, and it is that body of work — the M1 receptor studies, the colitis and mast-cell studies, the diabetic-complication series, the bone work — that supplies essentially everything interesting here.

The structural claim itself is secondary literature. That shatavarin IV — and by extension shatavarin I and the rest of the series — is “a glycoside of sarsasapogenin” carrying two rhamnose and one glucose is stated in a 2025 review ^{21Reference 21Banerjee P et al. · 2025An updated insight on the chemistry, ethnobotany, and health benefits of Asparagus racemosus (shatavari): with a special emphasis on shatavarin IVView study →}, not established by a primary structure-elucidation paper cited here. It is very likely correct — sarsasapogenin glycosides have been directly characterised from Asparagus adscendens and A. racemosus ^{1,22Reference 1Mustafa NH et al. · 2022Chemistry, biosynthesis and pharmacology of sarsasapogenin: a potential natural steroid molecule for new drug design, development and therapyView study →Reference 22Sidiq T et al. · 2011A novel sarsasapogenin glycoside from Asparagus racemosus elicits protective immune responses against HBsAgView study →} — but it should be read as a well-supported convention rather than a verified fact here.

And the naming in this series is genuinely unreliable. The originally published structures of shatavarins I and IV — the two flagship molecules — were wrong, with misassigned glycosidic linkages, and were formally revised by Hayes and colleagues in 2006 ^{39Reference 39Hayes PY et al. · 2006Structural revision of shatavarins I and IV, the major components from the roots of Asparagus racemosusView study →}. At least four independent naming series overlap on the same molecules: the same compounds appear in the literature as shatavarins, asparinins, asparosides, curillins/curillosides and schidigerasaponins — shatavarin I is also asparoside B, shatavarin IV is also asparinin B, and asparanin A is also schidigerasaponin D5 ^{40Reference 40Hayes PY et al. · 2008Steroidal saponins from the roots of Asparagus racemosusView study →}. Anyone reconciling a shatavari phytochemistry claim across two papers should assume the names may not mean what they appear to. Sarsasapogenin itself is comparatively stable nomenclature — it is also written sarsapogenin and was originally parigenin — but the glycosides it sits under are not.

And the one quantitative measurement complicates the picture. A validated HPTLC survey of ten North Indian Asparagus species found the highest sarsasapogenin content in the cladodes of A. racemosus (11.20 ± 0.025 mg/g dry weight) and in the roots of A. officinalis — ordinary garden asparagus — at 5.95 ± 0.024 mg/g ^{20Reference 20Mawal P et al. · 2026Comparative HPTLC analysis of shatavarin IV, sarsasapogenin, caffeic acid, β-sitosterol and lupeol in roots and cladodes of ten Asparagus L. ssp. from North IndiaView study →}. Shatavari products are made from the root, whose sarsasapogenin figure that study does not headline. Anyone reasoning from “shatavari is rich in sarsasapogenin” to a dose is reasoning past the data.

One citation in circulation for this claim does not say what it is said to say. The “phytoestrogenic aglycone implicated in oestrogen-receptor binding” attribution most often attached to sarsasapogenin traces to O’Leary 2021 ^{27Reference 27O’Leary MF et al. · 2021Shatavari supplementation in postmenopausal women improves handgrip strength and increases vastus lateralis myosin regulatory light chain phosphorylation but does not alter markers of bone turnoverView study →} — which is a 6-week randomised trial of whole shatavari extract in 20 postmenopausal women, measuring handgrip strength, myosin regulatory light chain phosphorylation and bone-turnover markers. It measured no sapogenin, ran no receptor assay, and found no change in bone turnover. Its only phytoestrogen content is a single unreferenced sentence in the introduction. It is a legitimate whole-plant trial and it is cited as one here; it is not evidence about this molecule.

What this means for the shatavari monograph. The mechanistic bridge from shatavari’s clinical menopause results to “phytoestrogenic saponins on a sarsasapogenin aglycone” is a plausible story with no measurement behind it at the molecule level, and with the one direct HPG-axis measurement running the other way ^{12Reference 12Hu K et al. · 2020Study on the mechanism of sarsasapogenin in treating precocious puberty by regulating the HPG axisView study →}. It should be stated as a hypothesis.

Isolate vs. Plant Studies

Almost uniquely for this batch, the isolate is nearly all the evidence there is — and that is not a strength here, because the isolate evidence is all in rodents. There is no clinical trial of sarsasapogenin. The human trials belong to whole plants: shatavari root extract for menopausal symptoms and muscle function ^{27Reference 27O’Leary MF et al. · 2021Shatavari supplementation in postmenopausal women improves handgrip strength and increases vastus lateralis myosin regulatory light chain phosphorylation but does not alter markers of bone turnoverView study →}, and, as the negative control on the entire hormone-precursor story, wild yam cream, which moved no hormone at all ^{28Reference 28Komesaroff PA et al. · 2001Effects of wild yam extract on menopausal symptoms, lipids and sex hormones in healthy menopausal womenView study →}.

Two attribution traps recur. First, source drift: the strong pharmacology is Anemarrhena, routinely reported under the more marketable name of shatavari or sarsaparilla. Second, derivative drift: several of the most-cited results — sarsasapogenin-AA13’s Aβ-clearance work ^{15Reference 15Huang C et al. · 2017Sarsasapogenin-AA13 ameliorates Aβ-induced cognitive deficits via improving neuroglial capacity on Aβ clearance and antiinflammationView study →}, YY-21’s rapid antidepressant effect ^{16Reference 16Guo F et al. · 2016The rapid antidepressant and anxiolytic-like effects of YY-21 involve enhancement of excitatory synaptic transmission via activation of mTOR signaling in the mPFCView study →}, the triazolyl hybrids ^{1Reference 1Mustafa NH et al. · 2022Chemistry, biosynthesis and pharmacology of sarsasapogenin: a potential natural steroid molecule for new drug design, development and therapyView study →} — belong to semi-synthetic derivatives that are not the natural molecule and cannot occur in a plant. Where the parent has been tested head-to-head against its own glycoside it wins ^{7,8Reference 7Lim SM et al. · 2015AnimalTimosaponin AIII and its metabolite sarsasapogenin ameliorate colitis in mice by inhibiting NF-κB and MAPK activation and restoring Th17/Treg cell balanceView study →Reference 8Lee B et al. · 2010Inhibitory effects of steroidal timosaponins isolated from the rhizomes of Anemarrhena asphodeloides against passive cutaneous anaphylaxis reaction and pruritusView study →}; where it has been tested against its own derivatives it loses ^{37Reference 37An RF et al. · 2025Design, synthesis and cytotoxic activity of novel lipophilic cationic derivatives of diosgenin and sarsasapogeninView study →}. Both facts are informative, and neither is a herb result.

Prevalence in Nature

Sarsasapogenin occurs across the Asparagaceae and Smilacaceae and into a few unrelated monocots, always as glycosides and almost never free.

Source	Part	Form it occurs as	Note
Sarsaparilla (Smilax spp.)	root/rhizome	Sarsasaponin/parillin and related spirostanol glycosides	The eponym; S. officinalis yields characterised sarsasapogenin trisaccharides 23Reference 23Bernardo RR et al. · 1996Steroidal saponins from Smilax officinalisView study →, and S. sieboldii carries sarsasapogenin/tigogenin-type saponins across leaf, stem and rhizome 30Reference 30Avula B et al. · 2023Avula B, Bae JY, Ahn J, et al. (2023). 6-Oxofurostane and (iso)spirostane types of saponins in Smilax sieboldii: UHPLC-QToF-MS/MS and GNPS-molecular networking approach. International Journal of Molecular Sciences. https://pubmed.ncbi.nlm.nih.gov/37511246/View study →
Anemarrhena asphodeloides (zhi mu)	rhizome	Timosaponins A-III, B-II, B-III	The source of essentially all the strong pharmacology 7,9,32Reference 7Lim SM et al. · 2015AnimalTimosaponin AIII and its metabolite sarsasapogenin ameliorate colitis in mice by inhibiting NF-κB and MAPK activation and restoring Th17/Treg cell balanceView study →Reference 9Sun Y et al. · 2015In vitroMetabolites characterization of timosaponin AIII in vivo and in vitro by using liquid chromatography-mass spectrometryView study →Reference 32Wang Y et al. · 2014ReviewThe genus Anemarrhena Bunge: a review on ethnopharmacology, phytochemistry and pharmacologyView study →
Shatavari (Asparagus racemosus)	root, cladodes	Shatavarins I–VI	11.2 mg/g dry weight in cladodes 20Reference 20Mawal P et al. · 2026Comparative HPTLC analysis of shatavarin IV, sarsasapogenin, caffeic acid, β-sitosterol and lupeol in roots and cladodes of ten Asparagus L. ssp. from North IndiaView study →; a distinct sarsasapogenin glycoside (“immunoside”) isolated from root 22Reference 22Sidiq T et al. · 2011A novel sarsasapogenin glycoside from Asparagus racemosus elicits protective immune responses against HBsAgView study →
Garden asparagus (A. officinalis)	root	Spirostanol glycosides	5.95 mg/g dry weight — higher in root than most of its medicinal relatives 20Reference 20Mawal P et al. · 2026Comparative HPTLC analysis of shatavarin IV, sarsasapogenin, caffeic acid, β-sitosterol and lupeol in roots and cladodes of ten Asparagus L. ssp. from North IndiaView study →
Safed musli (A. adscendens)	root, fruit	25S-5β-spirostanol glycosides (asparanins C, D)	Directly characterised 1Reference 1Mustafa NH et al. · 2022Chemistry, biosynthesis and pharmacology of sarsasapogenin: a potential natural steroid molecule for new drug design, development and therapyView study →
Yucca (Yucca schidigera)	—	Sarsasapogenin + smilagenin saponins	The commercial saponin material used as a Narthecium toxicity surrogate 26Reference 26Flåøyen A et al. · 2002Ruminal metabolism in sheep of saponins from Yucca schidigeraView study →
Bog asphodel (Narthecium ossifragum)	leaves, flower stems	Sarsasapogenin:smilagenin glycosides in a 9:1 ratio	Implicated in alveld, a hepatogenous photosensitisation of sheep 25Reference 25Flåøyen A · 1997Metabolism of saponins from Narthecium ossifragum — a plant implicated in the aetiology of alveld, a hepatogenous photosensitization of sheepView study →

Agave americana is often listed alongside these, but its characterised anti-inflammatory sapogenins are hecogenin and tigogenin, not sarsasapogenin ^{1Reference 1Mustafa NH et al. · 2022Chemistry, biosynthesis and pharmacology of sarsasapogenin: a potential natural steroid molecule for new drug design, development and therapyView study →}; treat the Agave attribution as unverified. In Smilax the sapogenins co-occur with a quite different phenolic chemistry — astilbin, engeletin, resveratrol — so no Smilax effect should be attributed to the sapogenin fraction by default.

Discovery & Synthesis

Sarsaparilla root was analysed chemically long before anyone understood what a steroid was. Frederick Power and Arthur Salway published their “Chemical examination of sarsaparilla root” in the Journal of the Chemical Society in 1914, isolating and naming the sapogenin they obtained on hydrolysis of the root’s saponin ^{2Reference 2Power FB · 1914XXV.—Chemical examination of sarsaparilla rootView study →}. It was known for a time as parigenin, after parillin, the glycoside it came from.

Its structural elucidation belongs to the heroic age of steroid chemistry. Through the 1930s and 1940s Russell Marker’s group at Penn State established the spirostane skeleton and, crucially, worked out how to degrade the spiroketal side chain — the transformation now called the Marker degradation — publishing the definitive survey of steroidal sapogenins in 1947 ^{3Reference 3MARKER RE · 1947Steroidal sapogeninsView study →}. Sarsasapogenin was among the sapogenins that chemistry was developed on. The industrial prize, however, went to diosgenin: because diosgenin carries a Δ⁵ double bond, its degradation yields 16-dehydropregnenolone directly, and Mexican Dioscorea became the feedstock of the twentieth-century steroid industry. Sarsaparilla’s sapogenin, saturated at that position, was left behind — which is why the hormone myth latched onto wild yam while sarsaparilla kept a vaguer “plant steroid” reputation.

Production today is by extraction and hydrolysis, not synthesis. The standard laboratory route extracts Anemarrhena rhizome with 95% ethanol at 70 °C and purifies over macroporous resin ^{1Reference 1Mustafa NH et al. · 2022Chemistry, biosynthesis and pharmacology of sarsasapogenin: a potential natural steroid molecule for new drug design, development and therapyView study →}; a cheaper published alternative hydrolyses sarsaparilla tincture directly — 45% ethanol at room temperature extracts the saponin without the gummy precipitate that plagues conventional methods, and acid hydrolysis of the tincture approaches 100% conversion, yielding sarsasapogenin plus smilagenin from epimerisation ^{24Reference 24Love J · 2020Acid hydrolysis of saponins extracted in tinctureView study →}. The compound remains expensive as a reference standard, and is not manufactured at scale for any therapeutic purpose.

Patents: not yet researched.

Toxicity & Safety

Sarsasapogenin carries a low flag — but that reflects an absence of evidence, not a clean safety file. There is no isolate toxicology package, no human exposure data, and no regulatory review of the pure compound anywhere. What exists is a long history of consuming the parent plants, one clear endocrine signal in an animal model, and a species-specific hazard in ruminants.

Safety at a Glance

✅ Low / no toxicity

• Long dietary and medicinal precedent for the source plants. Sarsaparilla root (including as a root-beer flavouring), shatavari and Anemarrhena have centuries of use; the sapogenin arrives only after gut bacteria hydrolyse the saponins, at unquantified levels.
• Not a saponin, so not haemolytic. The membrane-lysing surfactant behaviour that complicates this class belongs to the sugar-bearing glycosides, not to the free aglycone.
• It suppresses the reproductive axis in an animal model. In rats it lowered LH, FSH and oestradiol and downregulated hypothalamic GnRH and Kiss-1 — the basis of its precocious-puberty research. This is not a hormone-neutral molecule, and concentrated sapogenin exposure in children, adolescents or people managing fertility has never been studied.
• No human data of any kind. No clinical trial, no dose, no pharmacokinetics in people, no drug-interaction study, no genotoxicity or repeat-dose package.
• A long half-life and a dose you cannot know. ~15–18 h in rats with dose-linear exposure, and delivery from a herb that depends on the batch’s saponin content and on individual gut flora.

Full Safety & Interactions Detail

What the “low” badge is and is not. It reflects the absence of acute toxicity signals across a substantial rodent literature (20–100 mg/kg oral doses for 9–18 weeks in multiple laboratories, with no toxicity reported as an outcome) plus the dietary precedent of the source plants. It is not a clearance: no study in this literature was designed as a toxicology study, and reporting of adverse findings in efficacy studies is unreliable.

The endocrine signal is the one that would change the badge. The precocious-puberty work is well-conducted and unambiguous — sarsasapogenin delayed vaginal opening, shrank uterine and ovarian coefficients, thinned the uterine wall and downregulated the hypothalamic GnRH/Kiss-1/GPR54 system with corresponding falls in LH, FSH and oestradiol ^{12Reference 12Hu K et al. · 2020Study on the mechanism of sarsasapogenin in treating precocious puberty by regulating the HPG axisView study →}. Read as safety rather than efficacy, that is HPG-axis suppression from an oral sapogenin. Nobody has looked for it at herbal exposure levels, and nobody has looked for it in males.

Ruminant hepatotoxicity — real, but not a human hazard. Sarsasapogenin-bearing plants cause alveld, a hepatogenous photosensitisation of sheep grazing bog asphodel (Narthecium ossifragum), whose saponins are 9:1 sarsasapogenin:smilagenin glycosides ^{25Reference 25Flåøyen A · 1997Metabolism of saponins from Narthecium ossifragum — a plant implicated in the aetiology of alveld, a hepatogenous photosensitization of sheepView study →}. The mechanism is specific to ruminant physiology: rumen hydrolysis and C-3 epimerisation produce epi-sapogenins that are conjugated in the liver and precipitate in bile ducts. Lambs dosed with crystallised Yucca schidigera saponins at 55 mg/kg live weight daily for 11 days showed no sign of toxicity, and the metabolic route was identical ^{26Reference 26Flåøyen A et al. · 2002Ruminal metabolism in sheep of saponins from Yucca schidigeraView study →} — so the hazard tracks the dose and the grazing pattern, not the molecule alone. It does not transfer to human oral use, but it is why sapogenin-rich forage is a veterinary concern.

Interactions. None studied. The plausible ones are unexamined rather than absent: a molecule that suppresses NF-κB and NLRP3, is co-administered with corticosteroids in half the published disease models ^{1Reference 1Mustafa NH et al. · 2022Chemistry, biosynthesis and pharmacology of sarsasapogenin: a potential natural steroid molecule for new drug design, development and therapyView study →}, and downregulates PAR-1 ^{14Reference 14Kong L et al. · 2021Sarsasapogenin ameliorates diabetes-associated memory impairment and neuroinflammation through down-regulation of PAR-1 receptorView study →} has obvious theoretical overlap with immunosuppressants, corticosteroids and antiplatelet agents. There is no CYP or transporter data.

Reproductive note (prose only). Beyond the HPG-axis findings above, no reproductive or developmental toxicity study exists for isolated sarsasapogenin, and no lactation data. The LactMed entry that mentions the compound is a monograph on wild asparagus the herb, not on the molecule, and concerns shatavari’s galactagogue use. Pregnancy and lactation decisions belong on the herb or product page where intake is actually decided.

Dosage

There is no human dose. Sarsasapogenin has never been administered to people as an isolated compound, is not sold as a single-ingredient supplement, and has no established or investigational dose in any indication.

The published rodent doses are given below only so that the research can be read accurately. They are not human doses and do not scale to one.

Herbal exposure is indirect and unquantified. Sarsaparilla, shatavari and Anemarrhena preparations deliver saponins, not the sapogenin; how much aglycone is liberated depends on the saponin content of that batch and on the individual’s gut microbiota ^{7,8,9Reference 7Lim SM et al. · 2015AnimalTimosaponin AIII and its metabolite sarsasapogenin ameliorate colitis in mice by inhibiting NF-κB and MAPK activation and restoring Th17/Treg cell balanceView study →Reference 8Lee B et al. · 2010Inhibitory effects of steroidal timosaponins isolated from the rhizomes of Anemarrhena asphodeloides against passive cutaneous anaphylaxis reaction and pruritusView study →Reference 9Sun Y et al. · 2015In vitroMetabolites characterization of timosaponin AIII in vivo and in vitro by using liquid chromatography-mass spectrometryView study →}. Since even the plant-level content varies by species and by part — 11.2 mg/g in A. racemosus cladodes versus 5.95 mg/g in A. officinalis root ^{20Reference 20Mawal P et al. · 2026Comparative HPTLC analysis of shatavarin IV, sarsasapogenin, caffeic acid, β-sitosterol and lupeol in roots and cladodes of ten Asparagus L. ssp. from North IndiaView study →} — no meaningful sapogenin dose can be inferred from a herb label. Dose the herb by its own monograph, not by this molecule.

References

1. Mustafa NH, Sekar M, Fuloria S, et al. (2022). Chemistry, biosynthesis and pharmacology of sarsasapogenin: a potential natural steroid molecule for new drug design, development and therapy. Molecules. https://pubmed.ncbi.nlm.nih.gov/35335393/
2. Power FB, Salway AH (1914). XXV.—Chemical examination of sarsaparilla root. Journal of the Chemical Society, Transactions 105:201–219. https://doi.org/10.1039/CT9140500201
3. MARKER RE, WAGNER RB (1947). Steroidal sapogenins. Journal of the American Chemical Society. https://pubmed.ncbi.nlm.nih.gov/20262743/
4. Hu Y, Xia Z, Sun Q, Orsi A, Rees D (2005). A new approach to the pharmacological regulation of memory: sarsasapogenin improves memory by elevating the low muscarinic acetylcholine receptor density in brains of memory-deficit rat models. Brain Research. https://pubmed.ncbi.nlm.nih.gov/16226729/
5. Hu Y, Wang Z, Zhang R, et al. (2010). Regulation of M1-receptor mRNA stability by smilagenin and its significance in improving memory of aged rats. Neurobiology of Aging. https://pubmed.ncbi.nlm.nih.gov/18676061/
6. Kashyap P, Muthusamy K, Niranjan M, Trikha S, Kumar S (2020). Sarsasapogenin: a steroidal saponin from Asparagus racemosus as multi target directed ligand in Alzheimer’s disease. Steroids. https://pubmed.ncbi.nlm.nih.gov/31672628/
7. Lim SM, Jeong JJ, Kang GD, Kim KA, Choi HS, Kim DH (2015). Timosaponin AIII and its metabolite sarsasapogenin ameliorate colitis in mice by inhibiting NF-κB and MAPK activation and restoring Th17/Treg cell balance. International Immunopharmacology. https://pubmed.ncbi.nlm.nih.gov/25698557/
8. Lee B, Trinh HT, Jung K, Han SJ, Kim DH (2010). Inhibitory effects of steroidal timosaponins isolated from the rhizomes of Anemarrhena asphodeloides against passive cutaneous anaphylaxis reaction and pruritus. Immunopharmacology and Immunotoxicology. https://pubmed.ncbi.nlm.nih.gov/20095799/
9. Sun Y, Liu L, Peng Y, et al. (2015). Metabolites characterization of timosaponin AIII in vivo and in vitro by using liquid chromatography-mass spectrometry. Journal of Chromatography B. https://pubmed.ncbi.nlm.nih.gov/26134298/
10. Yang B, Liu Z, Hu J, Lai X, Xia P (2016). Quantitative determination of sarsasapogenin in rat plasma using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B. https://pubmed.ncbi.nlm.nih.gov/27107248/
11. Wang F, Zhang F, Lin B, Xiao W, Wang X, Wang N (2025). Sarsasapogenin stimulates angiogenesis and osteogenesis coupling to treat estrogen deficiency-induced osteoporosis by activating the GPX4/SLIT3/ROBO1 axis. Phytomedicine. https://pubmed.ncbi.nlm.nih.gov/39637471/
12. Hu K, Sun W, Li Y, et al. (2020). Study on the mechanism of sarsasapogenin in treating precocious puberty by regulating the HPG axis. Evidence-Based Complementary and Alternative Medicine. https://pubmed.ncbi.nlm.nih.gov/32831859/
13. Zhang YM, Zheng T, Huang TT, et al. (2021). Sarsasapogenin attenuates Alzheimer-like encephalopathy in diabetes. Phytomedicine. https://pubmed.ncbi.nlm.nih.gov/34333330/
14. Kong L, Liu Y, Zhang YM, et al. (2021). Sarsasapogenin ameliorates diabetes-associated memory impairment and neuroinflammation through down-regulation of PAR-1 receptor. Phytotherapy Research. https://pubmed.ncbi.nlm.nih.gov/33885189/
15. Huang C, Dong D, Jiao Q, Pan H, Ma L, Wang R (2017). Sarsasapogenin-AA13 ameliorates Aβ-induced cognitive deficits via improving neuroglial capacity on Aβ clearance and antiinflammation. CNS Neuroscience & Therapeutics. https://pubmed.ncbi.nlm.nih.gov/28466999/
16. Guo F, Zhang B, Fu Z, et al. (2016). The rapid antidepressant and anxiolytic-like effects of YY-21 involve enhancement of excitatory synaptic transmission via activation of mTOR signaling in the mPFC. European Neuropsychopharmacology. https://pubmed.ncbi.nlm.nih.gov/27211904/
17. Feng B, Zhao XY, Song YZ, Liang WN, Liu JL (2017). Sarsasapogenin reverses depressive-like behaviors and nicotinic acetylcholine receptors induced by olfactory bulbectomy. Neuroscience Letters. https://pubmed.ncbi.nlm.nih.gov/27988349/
18. Peng J, Zhao K, Zhu J, et al. (2020). Sarsasapogenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents lipopolysaccharide-induced bone loss in vivo. Drug Design, Development and Therapy. https://pubmed.ncbi.nlm.nih.gov/32943842/
19. Bao W, Pan H, Lu M, Ni Y, Zhang R, Gong X (2007). The apoptotic effect of sarsasapogenin from Anemarrhena asphodeloides on HepG2 human hepatoma cells. Cell Biology International. https://pubmed.ncbi.nlm.nih.gov/17400003/
20. Mawal P, Kapoor M, Pradhan SK, Rani J, Gupta RC (2026). Comparative HPTLC analysis of shatavarin IV, sarsasapogenin, caffeic acid, β-sitosterol and lupeol in roots and cladodes of ten Asparagus L. ssp. from North India. Natural Product Research. https://pubmed.ncbi.nlm.nih.gov/39319375/
21. Banerjee P, Das A, Kumar P, Chakraborty S, Jalan K (2025). An updated insight on the chemistry, ethnobotany, and health benefits of Asparagus racemosus (shatavari): with a special emphasis on shatavarin IV. Journal of the American Nutrition Association. https://pubmed.ncbi.nlm.nih.gov/40334116/
22. Sidiq T, Khajuria A, Suden P, et al. (2011). A novel sarsasapogenin glycoside from Asparagus racemosus elicits protective immune responses against HBsAg. Immunology Letters. https://pubmed.ncbi.nlm.nih.gov/21035507/
23. Bernardo RR, Pinto AV, Parente JP (1996). Steroidal saponins from Smilax officinalis. Phytochemistry. https://pubmed.ncbi.nlm.nih.gov/8862038/
24. Love J, Simons CR (2020). Acid hydrolysis of saponins extracted in tincture. PLoS One. https://pubmed.ncbi.nlm.nih.gov/33382809/
25. Flåøyen A, Wilkins AL (1997). Metabolism of saponins from Narthecium ossifragum — a plant implicated in the aetiology of alveld, a hepatogenous photosensitization of sheep. Veterinary Research Communications. https://pubmed.ncbi.nlm.nih.gov/9232777/
26. Flåøyen A, Wilkins AL, Sandvik M (2002). Ruminal metabolism in sheep of saponins from Yucca schidigera. Veterinary Research Communications. https://pubmed.ncbi.nlm.nih.gov/11922485/
27. O’Leary MF, Jackman SR, Sabou VR, et al. (2021). Shatavari supplementation in postmenopausal women improves handgrip strength and increases vastus lateralis myosin regulatory light chain phosphorylation but does not alter markers of bone turnover. Nutrients. https://pubmed.ncbi.nlm.nih.gov/34959836/
28. Komesaroff PA, Black CV, Cable V, Sudhir K (2001). Effects of wild yam extract on menopausal symptoms, lipids and sex hormones in healthy menopausal women. Climacteric. https://pubmed.ncbi.nlm.nih.gov/11428178/
29. Narayanan PL, Vellapandian C (2025). Screening of optimal phytoconstituents through in silico docking, toxicity, pharmacokinetic, and molecular dynamics approach for fighting against polycystic ovarian syndrome. Current Pharmaceutical Design. https://pubmed.ncbi.nlm.nih.gov/39513314/
30. Avula B, Bae JY, Ahn J, et al. (2023). 6-Oxofurostane and (iso)spirostane types of saponins in Smilax sieboldii: UHPLC-QToF-MS/MS and GNPS-molecular networking approach. International Journal of Molecular Sciences. https://pubmed.ncbi.nlm.nih.gov/37511246/
31. Choi YH (2023). Reduction of high glucose-induced oxidative injury in human retinal pigment epithelial cells by sarsasapogenin through inhibition of ROS generation and inactivation of NF-κB/NLRP3 inflammasome pathway. Genes & Genomics. https://pubmed.ncbi.nlm.nih.gov/37354257/
32. Wang Y, Dan Y, Yang D, et al. (2014). The genus Anemarrhena Bunge: a review on ethnopharmacology, phytochemistry and pharmacology. Journal of Ethnopharmacology. https://pubmed.ncbi.nlm.nih.gov/24556224/
33. Mandlik DS, Mandlik SK, Patel S (2021). Protective effect of sarsasapogenin in TNBS induced ulcerative colitis in rats associated with downregulation of pro-inflammatory mediators and oxidative stress. Immunopharmacology and Immunotoxicology. https://pubmed.ncbi.nlm.nih.gov/34338577/
34. Yuan Q, Li Y, Shen K, et al. (2026). Sarsasapogenin attenuates renal ischemia-reperfusion injury by inhibiting the NF-κB pathway and NLRP3 inflammasome-mediated pyroptosis. International Immunopharmacology. https://pubmed.ncbi.nlm.nih.gov/42166861/
35. Yang S, Fan L, Zhang R, et al. (2023). Smilagenin induces expression and epigenetic remodeling of BDNF in Alzheimer’s disease. Phytomedicine. https://pubmed.ncbi.nlm.nih.gov/37499345/
36. El-Ishaq A, Alshawsh MA, Chik ZB (2019). Evaluating the oestrogenic activities of aqueous root extract of Asparagus africanus Lam in female Sprague-Dawley rats and its phytochemical screening using GC/MS. PeerJ. https://pubmed.ncbi.nlm.nih.gov/31355056/
37. An RF, Wu KT, Pan J, et al. (2025). Design, synthesis and cytotoxic activity of novel lipophilic cationic derivatives of diosgenin and sarsasapogenin. Bioorganic & Medicinal Chemistry Letters. https://pubmed.ncbi.nlm.nih.gov/39778752/
38. Kaur B, Kumar S, Kaur A, Goel RK (2023). A network pharmacology approach to explore pharmacological mechanisms of Asparagus racemosus for ameliorative effect in epilepsy and comorbid progressive memory dysfunction. In Silico Pharmacology. https://pubmed.ncbi.nlm.nih.gov/37899966/
39. Hayes PY, Jahidin AH, Lehmann R, Penman K, Kitching W, De Voss JJ (2006). Structural revision of shatavarins I and IV, the major components from the roots of Asparagus racemosus. Tetrahedron Letters 47:6965–6969. https://doi.org/10.1016/j.tetlet.2006.07.121
40. Hayes PY, Jahidin AH, Lehmann R, Penman K, Kitching W, De Voss JJ (2008). Steroidal saponins from the roots of Asparagus racemosus. Phytochemistry. https://pubmed.ncbi.nlm.nih.gov/17936315/
41. Onlom C, Yang Y, Aisa HA, Woranuch N, Phrompittayarat W, Putalun W, Ingkaninan K (2017). Preparative and rapid purification of saponins from Asparagus racemosus root by high performance centrifugal partition chromatography. Natural Product Communications. https://pubmed.ncbi.nlm.nih.gov/30428221/

View all 41 references▾